Detalhe da pesquisa
1.
RAF1-MEK/ERK pathway-dependent ARL4C expression promotes ameloblastoma cell proliferation and osteoclast formation.
J Pathol
; 256(1): 119-133, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34622442
2.
The guanine nucleotide exchange factor VAV3 participates in ERBB4-mediated cancer cell migration.
J Biol Chem
; 295(33): 11559-11571, 2020 08 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-32561640
3.
An unbiased in vitro screen for activating epidermal growth factor receptor mutations.
J Biol Chem
; 294(24): 9377-9389, 2019 06 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30952700
4.
High frequency of BRAF V600E mutations in ameloblastoma.
J Pathol
; 232(5): 492-8, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24374844
5.
Overexpression of ERBB4 JM-a CYT-1 and CYT-2 isoforms in transgenic mice reveals isoform-specific roles in mammary gland development and carcinogenesis.
Breast Cancer Res
; 16(6): 501, 2014 Dec 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-25516216
6.
Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells.
EMBO Mol Med
; 16(3): 445-474, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38355749
7.
Wnt/ß-catenin-C-kit axis may play a role in adenoid cystic carcinoma prognostication.
Pathol Res Pract
; 254: 155148, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38277753
8.
Clear cell squamous cell carcinoma of the tongue exhibits characteristics as an undifferentiated squamous cell carcinoma.
Pathol Res Pract
; 235: 153909, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35552085
9.
The Semaphorin 3A-AKT axis-mediated cell proliferation in salivary gland morphogenesis and adenoid cystic carcinoma pathogenesis.
Pathol Res Pract
; 236: 153991, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35759940
10.
An Unbiased Functional Genetics Screen Identifies Rare Activating ERBB4 Mutations.
Cancer Res Commun
; 2(1): 10-27, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36860695
11.
Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors.
Nat Commun
; 13(1): 5614, 2022 09 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36153311
12.
An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer.
Nat Cancer
; 3(4): 402-417, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35422503
13.
Structural Basis for the Functional Changes by EGFR Exon 20 Insertion Mutations.
Cancers (Basel)
; 13(5)2021 Mar 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33807850
14.
Identification of Predictive ERBB Mutations by Leveraging Publicly Available Cell Line Databases.
Mol Cancer Ther
; 20(3): 564-576, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33323455
15.
Good Guy in Bad Company: How STRNs Convert PP2A into an Oncoprotein.
Cancer Cell
; 38(1): 20-22, 2020 07 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-32663465
16.
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation.
J Vis Exp
; (159)2020 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32510498
17.
Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway.
Cancer Cell
; 37(1): 104-122.e12, 2020 01 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31935369
18.
A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies.
Science
; 365(6453): 599-604, 2019 08 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31395785
19.
TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms.
Blood Adv
; 6(11): 3201-3206, 2022 06 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35026842
20.
ERBB4 promoter polymorphism is associated with poor distant disease-free survival in high-risk early breast cancer.
PLoS One
; 9(7): e102388, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25036186